In 2014, FDA gave pembrolizumab accelerated approval for melanoma.?
Today, the 3-year survival rate in melanoma patients is reported to be 40%.? ASCO president Dr. Julie Vose told NBC News, “This is something really different than what we have seen in the past.” ?nbcnews.to/25btTBv? via @nbcnews? @3SixtyPharma